Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma

Wang,Wei; Jiang,Haowen; Zhu,Hechen; Zhang,Hu; Gong,Jian; Zhang,Limin; Ding,Qiang

doi:10.3892/ol.2012.1091

Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma

Authors:
- Wei Wang
- Haowen Jiang
- Hechen Zhu
- Hu Zhang
- Jian Gong
- Limin Zhang
- Qiang Ding
View Affiliations

Affiliations: Institute of Urology, Fudan University, Shanghai 200040, P.R. China, Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China, Department of ICU, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Published online on: December 27, 2012 https://doi.org/10.3892/ol.2012.1091
Pages: 884-888

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High mobility group box 1 (HMGB1) and HMGB2 overexpression has been observed in several human tumor types, and is involved in cancer progression and prognosis. However, the clinicopathological significance of HMGB1 and HMGB2 expression in bladder carcinoma (BCa), particularly the involvement of these proteins in angiogenesis, remains unclear. In the present study, immunohistochemistry and real-time polymerase chain reaction (PCR) of HMGB1 and HMGB2 in 64 BCa patients revealed that HMGB1 and HMGB2 were overexpressed in BCa tissues compared with normal tissues, and were correlated with tumor clinical stage and pathological grade. In addition, correlation analysis of vascular endothelial growth factor (VEGF) and microvessel density (MVD) counts indicated that the overexpression of HMGB1 and HMGB2 was also correlated with angiogenesis. We conclude that HMGB proteins act as key regulators in the progression and angiogenesis of bladder carcinoma, and serve as potential diagnostic and therapeutic targets.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2	Ghoneim MA, Abdel-Latif M, el-Mekresh M, et al: Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol. 180:121–127. 2008.PubMed/NCBI
3	Vishnu P, Mathew J and Tan WW: Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther. 4:97–113. 2011.PubMed/NCBI
4	van Beijnum JR, Buurman WA and Griffioen AW: Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis. 11:91–99. 2008.PubMed/NCBI
5	Zhang J, McCauley MJ, Maher LJ III, et al: Mechanism of DNA flexibility enhancement by HMGB proteins. Nucleic Acids Res. 37:1107–1114. 2009. View Article : Google Scholar : PubMed/NCBI
6	Stros M, Polanská E, Struncová S and Pospísilová S: HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisome rase IIalpha. Nucleic Acids Res. 37:2070–2086. 2009. View Article : Google Scholar : PubMed/NCBI
7	Krynetskaia NF, Phadke MS, Jadhav SH and Krynetskiy EY: Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 8:864–872. 2009. View Article : Google Scholar : PubMed/NCBI
8	Balani P, Boulaire J, Zhao Y, et al: High mobility group box2 promoter-controlled suicide gene expression enables targeted glioblastoma treatment. Mol Ther. 17:1003–1011. 2009. View Article : Google Scholar : PubMed/NCBI
9	Naglova H and Bucova M: HMGB1 and its physiological and pathological roles. Bratisl Lek Listy. 113:163–171. 2012.PubMed/NCBI
10	Franklin S, Chen H, Mitchell-Jordan S, et al: Quantitative analysis of the chromatin proteome in disease reveals remodeling principles and identifies high mobility group protein b2 as a regulator of hypertrophic growth. Mol Cell Proteomics. 11:M111.0142582012. View Article : Google Scholar
11	Dong Xda E, Ito N, Lotze MT, et al: High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother. 30:596–606. 2007.PubMed/NCBI
12	Yao X, Zhao G, Yang H, et al: Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol. 136:677–684. 2010. View Article : Google Scholar : PubMed/NCBI
13	Shen X, Hong L, Sun H, et al: The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer. Oncol Rep. 22:535–539. 2009.PubMed/NCBI
14	Kostova N, Zlateva S, Ugrinova I and Pasheva E: The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem. 337:251–258. 2010. View Article : Google Scholar : PubMed/NCBI
15	Sharma A, Ray R and Rajeswari MR: Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Cancer Invest. 26:843–851. 2008. View Article : Google Scholar : PubMed/NCBI
16	Gnanasekar M, Thirugnanam S and Ramaswamy K: Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol. 34:425–431. 2009.PubMed/NCBI
17	Song B, Song WG, Li ZJ, et al: Effect of HMGB1 silencing on cell proliferation, invasion and apoptosis of MGC-803 gastric cancer cells. Cell Biochem Funct. 30:11–17. 2012. View Article : Google Scholar : PubMed/NCBI
18	Rhodes DR, Yu J, Shanker K, et al: Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA. 101:9309–9314. 2004. View Article : Google Scholar : PubMed/NCBI
19	Jiao Y, Wang HC and Fan SJ: Growth suppression and radio-sensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin. 28:1957–1967. 2007. View Article : Google Scholar : PubMed/NCBI
20	Tang D, Kang R, Zeh HJ III and Lotze MT: High-mobility group box 1 and cancer. Biochim Biophys Acta. 1799:131–140. 2010. View Article : Google Scholar : PubMed/NCBI
21	Sitohy B, Nagy J and Dvorak H: Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res. 72:1909–1914. 2012. View Article : Google Scholar : PubMed/NCBI
22	Ajili F, Kacem M, Tounsi H, et al: Prognostic impact of angio-genesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34. Ultrastruct Pathol. 36:336–342. 2012. View Article : Google Scholar
23	Deniz H, Karakök M, Yagci F and Güldür ME: Evaluation of relationship between HIF-1alpha immunoreactivity and stage, grade, angiogenic profile and proliferative index in bladder urothelial carcinomas. Int Urol Nephrol. 42:103–107. 2012. View Article : Google Scholar
24	Yang GL, Zhang LH, Bo JJ, et al: Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol. 106:57–61. 2012. View Article : Google Scholar : PubMed/NCBI
25	Tang D, Kang R, Cheh CW, et al: HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. 29:5299–5310. 2010. View Article : Google Scholar : PubMed/NCBI
26	Todorova J and Pasheva E: High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues. Oncol Lett. 3:214–218. 2012.PubMed/NCBI
27	Pusterla T, de Marchis F, Palumbo R and Bianchi ME: High mobility group B2 is secreted by myeloid cells and has mitogenic and chemoattractant activities similar to high mobility group B1. Autoimmunity. 42:308–310. 2009. View Article : Google Scholar : PubMed/NCBI
28	Le XF, Lammayot A, Gold D, et al: Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem. 280:2092–2104. 2005.
29	van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, et al: Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene. Mar 5–2012.(Epub ahead of print). View Article : Google Scholar
30	Sachdev U, Cui X, Hong G, et al: High mobility group box 1 promotes endothelial cell angiogenic behavior in vitro and improves muscle perfusion in vivo in response to ischemic injury. J Vasc Surg. 55:180–191. 2012. View Article : Google Scholar : PubMed/NCBI
31	Urquidi V, Goodison S, Kim J, et al: Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary bio markers for bladder cancer detection. Urology. 79:1185.e1–6. 2012. View Article : Google Scholar : PubMed/NCBI
32	Chavakis E, Hain A, Vinci M, et al: High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res. 100:204–212. 2007. View Article : Google Scholar : PubMed/NCBI